drugset
Drugs / Ultra Rapid Lispro
last change Oct 2025 re-read 3 minutes ago

Ultra Rapid Lispro

also known as URLi
Developed for
type 1 diabetes mellitus
Investigated by
Eli Lilly and Company · Tel-Aviv Sourasky Medical Center

Trials 2

today NCT06600776 · Ph 4 NCT03830281 · Ph 3
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT03830281 Feb 2019 → Jan 2020 type 1 diabetes mellitus Eli Lilly and Company Completed No outcome recorded
Phase 41 trial
Phase 4 NCT06600776 Oct 2024 → Sep 2025 overdue type 1 diabetes mellitus Tel-Aviv Sourasky Medical Center Not yet recruiting No outcome recorded

Press releases naming this drug 3 releases

DateIssuerRelease
2019-06-09 Eli Lilly and Company Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions lilly.com ↗
2018-10-02 Eli Lilly and Company Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes lilly.com ↗
2018-06-23 Eli Lilly and Company New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes lilly.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Ultra Rapid Lispro ClinicalTrials.gov intervention name — accepted as the source's own label NCT06600776 ↗
1

NCT03830281 ↗
Known as URLi “Ultra Rapid Lispro (URLi)” NCT06600776 ↗
Route Subcutaneous “Administered SC” NCT03830281 ↗